[PSMA-targeted radioligand therapy in prostate cancer]

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Prostate-specific membrane antigen (PSMA) is a target for cancer therapy.
• Metastatic castration-resistant prostate cancer (mCRPC) requires novel treatment strategies.
• Radioligand therapy (RLT) utilizes radiolabeled molecules to target cancer cells.

Purpose of the Study:

• To evaluate the efficacy and toxicity of PSMA-targeted RLT in mCRPC patients.
• To summarize current applications and outcomes of PSMA-directed RLT in Germany.
• To assess the role of PSMA-targeted RLT in the context of existing mCRPC therapies.

Main Methods:

• Retrospective analysis of case series involving PSMA-targeted RLT (e.g., using Lutetium-177 labeled PSMA ligands like PSMA-617 or PSMA-I&T).
• Assessment of prostate-specific antigen (PSA) decrease as a measure of treatment response.
• Monitoring of adverse events, including hematologic and non-hematologic toxicities.

Main Results:

• PSMA-targeted RLT demonstrated a PSA decrease >50% in 30-60% of mCRPC patients.
• Low toxicity profile observed, with rare grade 3 toxicities and no grade 4 hematologic toxicity.
• Common non-hematologic adverse events included dry mouth, fatigue, and nausea.

Conclusions:

• PSMA-targeted RLT is an emerging treatment option for mCRPC, showing significant PSA response rates.
• The therapy is generally well-tolerated, with manageable side effects.
• Further prospective studies are needed to confirm survival benefits and establish its definitive role compared to standard therapies.